In the case of delivery of anti-CTLA4 to tbLN, it is likely that the tumor tissue outcompetes the non-diseased tissue in terms of ICI availability, thereby minimizing unwarranted off-target effects. This evidence concerns the gene CTLA4 and neoplasm.